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ABSTRACT 
The guanine derivative antiviral drug acyclovir (ACV) is one of the oldest molecules laying successful market until date, bei ng commercially 
available in various dosage forms for oral, topical and parenteral administrations. Clinical application of this drug is superior to new antiviral 
agents due to its potential values such as suppression of recurrence, safety profile, minimal drug interactions and being inexpensive. ACV is 
slightly water soluble, less permeable and poorly bioavailable, yet more potential antiviral molecule. The present study involves preparation 
and evaluation of floating microspheres using ACV as a model drug for improving the drug bioavailability by prolongation of gastric retention 
time.  Ethyl cellulose, hydroxyl propyl methyl cellulose microspheres loaded with ACV were prepared by solvent diffusion evaporation method. 
The microspheres had smooth surfaces with free-flowing and good-packing properties. The yield of the microspheres (F1-F6) was range from 
62.23±0.85 to73.32±0.65% and ethyl cellulose microspheres entrapped the maximum amount of the drug. Scanning electron microscopy 
confirmed their hollow structures with sizes in 198.3 nm. The prepared microspheres (F3) exhibited prolonged drug release and percentage 
buoyancy was found to 76.65±0.52. The formulated batches were evaluated for percentage yield, particle size measurement, flow properties, 
percent entrapment efficiency, swelling studies. The formulations were subjected to stability studies and In-vitro release and release kinetics 
data was subjected to different dissolution models. It was concluded that developed floating microspheres of ACV offers a suitable and practical 
approach for prolonged release of drug over an extended period of time and thus oral bioavailability, efficacy and patient compliance is 
improved. 
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INTRODUCTION 
Oral rout of administration is the most convenient and 
widely used method of drug administration and the 
development of stomach specific oral controlled-release drug 
delivery systems is a challenging job due to the variation of 
pH in different segments of the gastrointestinal tract, the 
fluctuation in gastric emptying time and the difficulty of 
localizing an oral delivery system in a selected region of the 
gastrointestinal tract. Rapid gastrointestinal transit can 
prevent the absorption of complete drug in the absorption 
zone and reduce the efficacy of the administered dose since 
the majority of drugs are absorbed in stomach or the upper 
part of small intestine [1,2]. To overcome the above 
discussed issues, many types of oral controlled drug delivery 
systems having prolonged gastric residence times have been 
reported such as: floating drug dosage systems (FDDS) [3-7], 
swelling or expanding system[8], mucoadhesive 
systems[9,10], modified-shape systems[11], high-density 
systems and other delayed gastric emptying devices[12]. 
FDDS have lower density than gastric fluids and thus remain 
buoyant in the stomach fluid without affecting the gastric 
emptying for a prolonged period of time. While the system is 
floating in the gastric fluid, the drug is released slowly from 
the system at a desired rate. Materials used for FDDS include 
carbon dioxide gas-forming agents (carbonate or 
bicarbonate compounds) [8, 13], highly swellable 
hydrocolloids and light mineral oils [14,15]. Multiple unit 
systems and floating systems prepared by solvent 
evaporation methods have also been developed [12, 16-20]. 
However, it has been shown that products based on a 
multiple unit system comprising many small units have 
advantages over single -unit preparations such as matrix 
tablets [21]. The gastric emptying of multiple unit dosage 
forms occur gradually, in a more consistent manner, with 
less individual variation [2, 22]. Multiple unit dosage forms 
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also have the potential to distribute widely over a large area 
in the stomach and small intestine, thus yielding a more 
predictable drug release by suppressing the effect of many 
variables in the gastrointestinal environment. As multiple 
unit dosage forms consist of many small units, less risk of 
dosage dumping is expected [23]. Acyclovir [9-(2-
hydroxyethoxymethyl)guanine; Zovirax] is a widely used 
antiviral drug for treating infectious diseases, such as genital 
herpes, chicken pox, varicella zoster infections, and herpes 
keratitis caused by herpes simplex virus. Oral absorption of 
acyclovir is highly variable, with an average bioavailability of 
20–26.7% in humans [24-26]. Moreover, due to its short 
halflife (t1/2) of approximately 2.5 h, repeated 
administration of high-dose acyclovir is usually required to 
achieve therapeutic efficacy. Floating microspheres are one 
of the multiparticulate delivery system and are prepared to 
obtain prolonged or controlled drug delivery to improve 
bioavailability and to target drug to specific sites. 
Microspheres can also offer advantages like limiting 
fluctuation within therapeutic range, reducing site effects, 
decreasing dosing frequency and improving patient 
compliance [27]. 
MATERIAL AND METHODS 
Material 
Acyclovir was obtained as a gift sample from Macleods 
Pharmaceuticals, Mumbai. Dichloromethane, ethanol and 
isopropyl alcohol were purchased from E. Merck (India) Ltd., 
Mumbai. Ethyl cellulose, hydroxyl propyl methyl cellulose 
was purchased from Loba Chem. Pvt. Ltd, Mumbai. Double 
distilled water was prepared freshly and used whenever 
required. All the chemicals used in this work were of 
analytical grade. 
Methods 
Determination of λ max of ACV 
Accurately weighed 10 mg of drug was dissolved in 10 ml of 
0.1 N HCl solutions in 10 ml of volumetric flask. The resulted 
solution 1000µg/ml and from this solution 1 ml pipette out 
and transfer into 10 ml volumetric flask and volume make up 
with 0.1 N HCl solution prepare suitable dilution to make it 
to a concentration range of 5-25μg/ml. The spectrum of this 
solution was run in 200-400 nm range in U.V. 
spectrophotometer (Labindia-3000+). A graph of 
concentration Vs absorbance was plotted. 
Preparation of floating microsphere of ACV 
Floating microspheres loaded with acyclovir were prepared 
using solvent diffusion-evaporation method using HPMC and 
EC in different ratio like 1:0.5, 1:1.5, 1:2 w/w. Drug and 
polymer in proportion of drug and polymers were dissolved 
in 1:2 mixture of solvent system of ethanol and 
dichloromethane. This clear solution was poured slowly in a 
thin stream into the aqueous solution of 1% polyvinyl 
alcohol. The emulsion was continuously stirred for 3 h at a 
speed of 500 rpm at 27±2°C. The floating microspheres were 
collected by decantation, while the non-floating 
microspheres were discarded. The microspheres were dried 
overnight at 40±2°C and stored in desicator. The 
compositions of the formulations were shown in Table 1.
 
Table 1 Formulations of the floating microspheres of ACV     
Sr. No Formulation Code Acyclovir (mg) 
HPMC  
(mg) 
EC 
(mg) 
1. F1 100 100 50 
2. F2 100 100 150 
3. F3 100 100 200 
4. F4 100 100 100 
5. F5 100 150 100 
6. F6 100 200 100 
 
Evaluation of microspheres      
Microscopic Observation of prepared Microsphere 
An optical microscope (cippon, Japan) with a camera 
attachment (Minolta) was used to observe the shape of the 
prepared microsphere formulation. 
Percentage Yield 
The prepared microspheres with a size range of 1μm to 
1000μm were collected and weighed from different 
formulations. The measured weight was divided by the total 
amount of all non-volatile components which were used for 
the preparation of the microspheres. 
          
                                            
                                 
      
Drug Entrapment 
The various formulations of the floating microspheres were 
subjected for drug content. 10 mg of floating microspheres 
from all batches were accurately weighed and crushed. The 
powder of microspheres were dissolved in 10 ml 0.1 N HCl 
and centrifuge at 1000 rpm. This supernatant solution is 
than filtered through whatmann filter paper No. 44. After 
filtration, from this solution 0.1 ml was taken out and diluted 
up to 10 ml with 0.1 N HCl. The percentage drug entrapment 
was calculated using calibration curve method 
Floating behavior 
Ten milligrams of the floating microspheres were placed in 
0.1 N HCl (100 ml). The mixture was stirred at 100 rpm in a 
magnetic stirrer. After 10 h, the layer of buoyant 
microsphere was pipetted and separated by filtration. 
Particles in the sinking particulate layer were separated by 
filtration. Particles of both types were dried in desiccators 
until a constant weight was obtained. Both the fractions of 
microspheres were weighed and buoyancy was determined 
by the weight ratio of floating particles to the sum of floating 
and sinking particles. 
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Measurement of mean particle size 
The mean size of the microspheres was determined by Photo 
Correlation Spectroscopy (PCS) on a submicron particle size 
analyzer (Malvern Instruments) at a scattering angle of 90°. 
A sample (0.5mg) of the microspheres suspended in 5 ml of 
distilled water was used for the measurement 
Determination of zeta potential 
The zeta potential of the drug-loaded microspheres was 
measured on a zeta sizer (Malvern Instruments) by 
determining the electrophoretic mobility in a micro 
electrophoresis flow cell. All the samples were measured in 
water at 25°C in triplicate.   
In-vitro Release Studies 
The drug release rate from floating microspheres was 
carried out using the USP type II (Electro Lab.) dissolution 
paddle assembly. A weighed amount of floating 
microspheres equivalent to 100 mg drug were dispersed in 
900 ml of 0.1 N HCI (pH=1.2) maintained at 37 ± 0.5°C and 
stirred at 55rpm. One ml sample was withdrawn at 
predetermined intervals and filtered and equal volume of 
dissolution medium was replaced in the vessel after each 
withdrawal to maintain sink condition. The collected 
samples analyzed spectrophotometrically at 242 nm to 
determine the concentration of drug present in the 
dissolution medium [28,29].  
Drug release kinetic data analysis 
Several kinetic models have been proposed to describe the 
release characteristics of a drug from matrix. The following 
three equations are commonly used, because of their 
simplicity and applicability. Equation 1, the zero-order 
model equation (Plotted as cumulative percentage of drug 
released vs time); Equation 2, Higuchi’s square-root equation 
(Plotted as cumulative percentage of drug released vs square 
root of time); and Equation 3, the Korsemeyer-Peppas 
equation (Plotted as Log cumulative percentage of drug 
released vs Log time). 
To study the release kinetics of Famotidinefrom the Floating 
microspheres the release data was fitted to these three 
equations 
Zero order equation: When a graph of the cumulative 
percentage of the drug released from the matrix against time 
is plotted, zero order release is linear in such a plot, 
indicating that the release rate is independent of 
concentration. 
Qt = k0.t ……………………… (1) 
Where Qt is the percentage of drug released at time t and k0 is 
the release rate constant; 
First order equation:- 
In (100-Qt) = In 100- kI.t ………………….. (2) 
                 Where kI is the release rate constant; 
 Higuchi’s equation (Wagner, 1969):- 
Qt = kH.t1/2    ……………………….. (3) 
                 Where KH is the Higuchi release rate constant 
  Korsemeyer-Peppas:- 
The curves plotted may have different slopes, and hence it 
becomes difficult to exactly pin-point which curve follows 
perfect zero order release kinetics. Therefore, to confirm the 
kinetics of drug release, data were also analyzed using 
Korsemeyer’s equation. 
 Qt/Q∞ = kKP.tn 
Where Qt/ Q∞ is the fraction of drug released at time t, kKPa 
constant compromising the structural and geometric 
characteristics of the device and n is the release exponent. 
The slope of the linear curve gives the ‘n’ value. Peppas 
stated that the above equation could adequately describe the 
release of solutes from slabs, spheres, cylinders and discs, 
regardless of the release mechanism. The value of ‘n’ gives an 
indication of the release mechanism. When n = 1, the release 
rate is independent of time (typical zero order release / case 
II transport); n = 0.5 for Fickian release (diffusion/ case I 
transport); and when 0.5 < n < 1, anomalous (non-Fickian or 
coupled diffusion/ relaxation) are implicated. Lastly, when n 
> 1.0 super case II transport is apparent.  ‘n’ is the slope 
value of log Mt/M∞   versus log time curve [30-32]. 
Stability studies 
Stability studies were carried out with optimized 
formulation which was stored for a period of 45 days at 
4±1°C, RT and 40±1°C. 
RESULTS AND DISCUSSION 
The λ max of ACV was found to be 242 nm by using U.V. 
spectrophotometer (Labindia-3000+) in linearity range 5-25 
µg/ml Fig.1, 2. The floating microspheres of ACV were 
prepared by solvent diffusion-evaporation method. 
Percentage yield of different formulation was determined by 
weighing the microspheres after drying.  The percentage 
yield of different formulation was in range of 62.23±0.85 
to73.32±0.65% Table 2. The maximum percentage yield was 
found in formulation F3, 73.32±0.65 as compare to all 
formulation. The drug entrapment efficacies of different 
formulations were in range of 62.23±0.54 to75.56±0.23 
%w/w. The maximum percentage drug entrapment was 
found in formulation F3 (75.56±0.23 % w/w) Table 3. To 
assess the floating properties, the microspheres were placed 
in 0.1N hydrochloric acid. The microspheres floated for 
prolonged time over the surface of the dissolution medium 
without any apparent gelation. Buoyancy percentage of the 
microspheres was in the range of 55.65±0.65 to76.65±0.52. 
The nature of the polymer influenced the floating behaviour 
of the microspheres Table 4. The maximum percentage yield, 
drug entrapment, percentage buoyancy and floating lag time 
was found to be formulation F3 in floating microsphere. The 
optimized formulation of F3 was subjected to further studies. 
The mean size of the microspheres was determined by photo 
correlation spectroscopy (PCS) on a submicron particle size 
analyzer (Horiba Instruments) at a scattering angle of 
90°.The results of measurement of mean particle size of 
optimized formulation F3 of floating microsphere was found 
to be 198.3nm Fig. 3. Results of zeta potential of optimized 
formulation F4 of floating microsphere was found --35.8 mV 
Fig. 4. 
 
Figure 1 UV spectra of pure drug (ACV) 
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Figure 2 Calibration curve of ACV in 0.1 N HCl at 242 nm 
Table 2 Percentage yield for different formulation 
Formulation Percentage Yield 
F1 69.98±0.98 
F2 70.12±0.95 
F3 73.32±0.65 
F4 65.56±0.58 
F5 62.23±0.85 
F6 66.56±0.32 
 
Table 3 Drug entrapment for different formulations 
Formulation 
Drug entrapment (% w/w) of 
prepared microsphere 
F1 65.56±0.95 
F2 69.98±0.65 
F3 75.56±0.23 
F4 62.23±0.54  
F5 59.98±0.52 
F6 63.32±0.45 
*Average of three determination (n=3) 
Table 4 Floating lag time and percentage buoyancy of 
floating microsphere 
Formulation 
Floating Lag 
Time (Sec.) 
Percentage 
Buoyancy 
F1 45±3 55.65±0.65 
to76.65±0.52 
F2 49±2 66.65±0.69 
F3 32±4 76.65±0.52 
F4 45±3 56.65±0.47 
F5 43±2 65.56±0.32 
F6 48±3 73.21±0.45 
 
 
Figure 3 Particle size data of optimized microsphere 
formulation F3 
 
Figure 4 Zeta potential data of floating microsphere F3 
The drug release from floating microspheres was found to be 
98.85 % at the end of 12 h for F3 Table 5. The In vitro drug 
release data of the optimized formulation was subjected to 
goodness of fit test by linear regression analysis according to 
zero order and first order kinetic equation, in order to 
determine the mechanism of drug release. When the 
regression coefficient values were compared, it was 
observed that an ‘r’ value of microsphere was maximum zero 
order i.e 0.958 hence indicating drug releases from 
formulations was found to follow zero order for floating 
microsphere Table 6 & 7 and Fig. 5 & 6. According to ICH 
guidelines, 3 months accelerated stability study at 40±2°c 
and 75±5% RH optimized formulations (F3) was carried out. 
It showed negligible change over time for parameters like 
appearance, drug content, dissolution and assay etc., No 
significant difference observed  in the drug content between 
initial and formulations stored at 40±2°c & 75±5% RH for 3 
months.
 
Table 5 Release study data of formulation F1-F6 
Time Percentage Drug Release  
(hr) F1 F2 F3 F4 F5 F6 29.98 
0.5 33.25 30.25 25.56 29.98 20.23 15.56 39.98 
1 46.65 41.25 30.56 39.98 26.65 23.32 46.65 
2 59.98 52.36 42.23 46.65 31.25 33.32 63.32 
4 73.23 69.98 60.32 63.32 46.65 45.56 80.56 
6 89.98 85.56 75.56 80.56 53.32 51.48 92.23 
8 99.23 90.23 82.56 92.23 63.32 56.65 99.23 
10 - 99.89 89.98 99.23 72.23 65.56 - 
12 - - 98.85 - 85.56 73.32 29.98 
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Table 6 Release Kinetics of optimized formulation of microsphere F-3 
Time 
(h) 
Square Root 
of 
Time(h)1/2 
Log 
Time 
Cumulative% 
Drug Release 
Log 
Cumulative % 
Drug Released 
Cumulative %  
Drug 
Remaining 
Log 
Cumulative % 
Drug 
Remaining 
0.5 0.707 -0.301 25.56 1.408 74.44 1.872 
1 1 0 30.56 1.485 69.44 1.842 
2 1.414 0.301 42.23 1.626 57.77 1.762 
4 2 0.602 60.32 1.780 39.68 1.599 
6 2.449 0.778 75.56 1.878 24.44 1.388 
8 2.828 0.903 82.56 1.917 17.44 1.242 
10 3.162 1 89.98 1.954 10.02 1.001 
12 3.464 1.079 98.85 1.995 1.15 0.061 
 
Table 7 Comparative study of regression coefficient for selection of optimized Formulation F-3 
Release Kinetics Zero order First order 
R2 0.958 0.866 
 
 
 
Figure 5 Zero order release kinetics 
 
 
Figure 6 First order release kinetics 
 
CONCLUSION 
In vitro data obtained for floating microspheres of ACV 
showed excellent floatability, good buoyancy and prolonged 
drug release. Microspheres of different size and drug content 
could be obtained by varying the formulation variables. 
Thus, the prepared floating microspheres may prove to be 
potential candidates for multiple-unit delivery devices 
adaptable to any intragastric condition. 
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